Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 9; pp. 2083 - 2089
• Main Authors: Fleischmann, Roy, Connolly, Sean E., Maldonado, Michael A., Schiff, Michael
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2016; John Wiley and Sons Inc
• Subjects: Abatacept - therapeutic use; Adalimumab - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - drug therapy; Biomarkers - blood; Colon; Health risk assessment; Humans; Methotrexate; Rheumatoid Arthritis; Severity of Illness Index

Objective To assess the ability of a multi‐biomarker disease activity (MBDA) test (Vectra DA) to reflect clinical measures of disease activity in patients enrolled in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic‐Naive RA Subjects with Background Methotrexate) trial. Methods In the A...